Form 4: Elanco CEO Jeffrey Simmons Reports Stock and Option Grants in Form 4 Filing

Elanco Animal Health's CEO, Jeffrey Simmons, reported the acquisition of restricted stock units and stock options in a recent Form 4 filing with the SEC.

Summary

• Jeffrey N. Simmons, CEO and Director of Elanco Animal Health Inc., filed a Form 4 with the SEC on March 5, 2025.
• The filing reports the grant of 265,252 restricted stock units and 556,587 stock options to Mr. Simmons on March 3, 2025.
• The restricted stock units vest in three equal installments on March 3, 2026, March 3, 2027, and March 3, 2028.
• The stock options also vest in three equal installments on March 3, 2026, March 3, 2027, and March 3, 2028, with an exercise price of $11.31.
• Mr. Simmons also acquired 14,891 deferred stock units that vest on December 31, 2026, and settle upon termination of employment.
• Following these transactions, Mr. Simmons directly owns 1,802,379 shares of Elanco common stock and indirectly owns 145,000 shares through a revocable trust.
• He also holds 556,587 employee stock options and 14,891 deferred stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as aligning management and shareholder interests.

Positives

• The grant of restricted stock units and stock options aligns the CEO's interests with those of the shareholders, incentivizing long-term performance.
• The vesting schedule encourages continued service and commitment from the CEO.

Industry Context

Form 4 filings are a routine part of executive compensation and are common across publicly traded companies. The size and structure of the grants are typical for a CEO of a company the size of Elanco.

Comparison to Industry Standards

• Executive compensation packages, including stock options and restricted stock units, are standard practice among publicly traded companies like Elanco.
• Companies such as Zoetis and Merck Animal Health also utilize similar equity-based compensation to align executive interests with shareholder value.
• The vesting schedules are also typical, designed to retain executives and incentivize long-term performance, mirroring practices seen in comparable companies.

Stakeholder Impact

• The grants incentivize the CEO to improve company performance, which benefits shareholders.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates